Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance.

Zhou Y

Open source

DOI
10.3389/fimmu.2026.1955015
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1955015,
  title = {Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance.},
  author = {Zhou Y},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1955015},
  url = {https://doi.org/10.3389/fimmu.2026.1955015}
}

RIS

TY  - JOUR
TI  - Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance.
AU  - Zhou Y
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1955015
UR  - https://doi.org/10.3389/fimmu.2026.1955015
ER  - 

APA

Y, Z. (2026). Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1955015

Source records